Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 15/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 15/20 | 0.63 |
| ▸ | CHRNB4 | P30926 | 15/20 | 0.63 |
| ▸ | CHRNA3 | P32297 | 15/20 | 0.63 |
| ▸ | CHRNA7 | P36544 | 12/20 | 0.63 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.47 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5938449 | 1.00 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5938442 | 1.00 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL5939647 | 0.99 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL5939653 | 0.99 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL5939661 | 0.99 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5940246 | 0.90 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5940251 | 0.90 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5940077 | 0.88 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5940074 | 0.88 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5938253 | 0.86 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287290-A1 | Azabicyclic compounds are central nervous system active agents | DART MICHAEL J | 2006-12-21 | — | — | US | claimed |
| US-7135484-B2 | Azabicyclic compounds are central nervous system active agents | ABBOTT LABORATORIES (US) | 2006-11-14 | — | — | US | claimed |
| EP-1539733-A2 | AZABICYCLIC COMPOUNDS ARE CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | Abbott Laboratories (US) | 2005-06-15 | — | — | EP | claimed |
| US-20040152724-A1 | Azabicyclic compounds are central nervous system active agents | ABBVIE INC. | 2004-08-05 | — | — | US | claimed |
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ABBOTT LABORATORIES | 2004-03-04 | — | — | US | claimed |
| WO-2004016604-A2 | AZABICYCLIC COMPOUNDS ARE CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2004-02-26 | — | — | WO | claimed |
| US-20060287290-A1 | Azabicyclic compounds are central nervous system active agents | DART MICHAEL J | 2006-12-21 | — | — | US | disclosed |
| US-7135484-B2 | Azabicyclic compounds are central nervous system active agents | ABBOTT LABORATORIES (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1539733-A2 | AZABICYCLIC COMPOUNDS ARE CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | Abbott Laboratories (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040152724-A1 | Azabicyclic compounds are central nervous system active agents | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ABBOTT LABORATORIES | 2004-03-04 | — | — | US | disclosed |
| WO-2004016604-A2 | AZABICYCLIC COMPOUNDS ARE CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152724-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHRNA6, CHRNA2 | CHRNB2 10/4885CHRNA4 9/4885CHRNB4 13/4885 |
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHRNA6, CHRNA2 | CHRNB2 10/4885CHRNA4 9/4885CHRNB4 13/4885 |
| US-20060287290-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHAT, CHRNA6 | CHRNB2 8/4885CHRNA4 9/4885CHRNB4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.